Investigation Alert: Alector, Inc. (ALEC) Under Scrutiny - Contact Levi & Korsinsky For Details

NEW YORK, NY / ACCESS Newswire / December 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation into Alector, Inc. ("Alector, Inc.") (NASDAQ:ALEC) concerning potential violations of the federal securities laws.

On October 22, 2025, Alector announced results from its Phase 2 INFRONT-3 clinical trial evaluating latozinemab (AL001) in patients with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). The company reported that "latozinemab did not demonstrate a clinical benefit" for slowing FTD-GRN progression in its 96-week double-blind trial.

Following this news, ALEC's stock price fell over 52% to open at $1.54 per share.

If you suffered a loss on your Alector, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212)363-7500

Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP